Global Age Related Macular Degeneration Treatment Market Growth (Status and Outlook) 2025-2031

According to this study, the global Age Related Macular Degeneration Treatment market size will reach US$ 9923 million by 2031.

Age-related macular degeneration (AMD) is a disease that blurs the sharp, central vision you need for “straight-ahead” activities such as reading, sewing, and driving. AMD affects the macula, the part of the eye that allows you to see fine detail.

The age-related macular degeneration (AMD) treatment market is driven by the increasing prevalence of AMD, particularly in the aging population. As the global elderly population grows, the demand for effective treatment options to manage and slow down AMD progression rises. Additionally, advancements in medical research and technology have led to the development of novel therapies, such as anti-VEGF drugs, which have significantly improved visual outcomes for AMD patients. However, challenges exist, including the high cost of treatment, especially for long-term therapies, and the need for early detection and diagnosis to ensure timely intervention. Overcoming these challenges through affordable treatment options, patient education, and continued research to identify new therapeutic targets will be crucial for the sustained growth of the age-related macular degeneration treatment market.

LPI (LP Information)' newest research report, the “Age Related Macular Degeneration Treatment Industry Forecast” looks at past sales and reviews total world Age Related Macular Degeneration Treatment sales in 2024, providing a comprehensive analysis by region and market sector of projected Age Related Macular Degeneration Treatment sales for 2025 through 2031. With Age Related Macular Degeneration Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Age Related Macular Degeneration Treatment industry.

This Insight Report provides a comprehensive analysis of the global Age Related Macular Degeneration Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Age Related Macular Degeneration Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Age Related Macular Degeneration Treatment market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Age Related Macular Degeneration Treatment and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Age Related Macular Degeneration Treatment.

This report presents a comprehensive overview, market shares, and growth opportunities of Age Related Macular Degeneration Treatment market by product type, application, key players and key regions and countries.

Segmentation by Type:
Lucentis
Eylea
Avastin
Other

Segmentation by Application:
Hospital
Clinic
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Regeneron Pharmaceuticals
Bayer HealthCare
Novartis
Roche
Kanghong Pharma

Please note: The report will take approximately 2 business days to prepare and deliver. Show more